Author

W. Ewert

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 2 Biophysics· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Organism:virus· 2 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1 Research Focus:chromatin & epigenetic regulation· 1 Approach:deep learning· 1 Assay:Hi-C· 1

Frequent Co-Authors

J. Lieske· 3 shared P. Y. A. Reinke· 3 shared S. Falke· 3 shared D. Turk· 2 shared F. TrostiD· 2 shared H. Andaleeb· 2 shared H. Ginn· 2 shared K. Lorenzen· 2 shared

Activity by Year

2019-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersBiochemistry

J. Lieske

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Structural elucidation and antiviral activity of cathepsin L inhibitors with carbonyl and epoxide warheads

S. Falke, J. Lieske, A. Herrmann, J. Loboda, S. Gunther, P. Y. A. Reinke, W. Ewert, K. Karnicar, A. Usenik, N. Lindic, A. Sekirnik, H. Tsuge, V. Turk, H. N. Chapman, W. Hinrichs, , A. Meents

The paper presents crystal structures of cathepsin L inhibitors and evaluates their antiviral activity against SARS-CoV-2.

bioRxiv · Aug 11, 2023 · PreprintBiochemistry

SARS-CoV-2 papain-like protease PLpro in complex with natural compounds reveal allosteric sites for antiviral drug design

V. Srinivasan, H. Brognaro, P. R. Prabhu, E. E. de Souza, S. Guenther, P. Y. A. Reinke, T. J. Lane, H. Ginn, H. Han, W. Ewert, J. Sprenger, F. H. M. Koua, S. Falke, N. Werner, H. Andaleeb, , P

This study identifies three natural compounds that inhibit SARS-CoV-2 PLpro by binding to the ISG15/Ub-S2 allosteric site, showing antiviral activity and potential for drug design.

Communications Biology · Aug 11, 2022Peer-reviewedBiochemistry

Inhibition of SARS-CoV-2 main protease by allosteric drug-binding

S. Guenther, P. Y. A. Reinke, Y. Fernandez-Garcia, J. Lieske, T. J. Lane, H. Ginn, F. Koua, C. Ehrt, W. Ewert, D. Oberthuer, O. Yefanov, S. Meier, K. Lorenzen, B. Krichel, J. Kopicki, , Schwi

The paper identifies 37 compounds binding to SARS-CoV-2 main protease through X-ray crystallography, with five non-peptidic compounds showing antiviral activity in cell-based assays.

bioRxiv · Nov 12, 2020Biophysics

Miswired enhancer logic drives translocation positive rhabdomyosarcoma

B. E. Gryder, M. Wachtel, K. Chang, O. E. Demerdash, N. G. Aboreden, W. Ewert, S. Pomella, W. Mohammed, R. Rota, J. S. Wei, Y. Song, B. Schaefer, C. R. Vakoc, J. Khan

The paper identifies a miswired enhancer logic driven by PAX3-FOXO1 translocation in rhabdomyosarcoma, disrupting normal transcription factor regulation and promoting undifferentiated proliferation.

bioRxiv · Sep 6, 2019 · PreprintCancer Biology